A Source for High Quality Research and Innovations

Esitys aiheesta: "A Source for High Quality Research and Innovations"— Esityksen transkriptio:

1 A Source for High Quality Research and Innovations
BioMediTech A Source for High Quality Research and Innovations

2 BMT Supervisory Board MEMBERS SUBSTITUTE MEMBERS
Martti Syrjälä – CEO, Finnish Red Cross Blood Service Anne Kallioniemi – Professor, UTA Harri Melin – Vice Rector, UTA Kari Varkila – CEO, Tampereen Lääkärikeskus (Koskiklinikka) Minna Kellomäki – Professor, TUT Ulla Ruotsalainen – Vice Rector, TUT SUBSTITUTE MEMBERS Kari Aranko – Director, Finnish Red Cross Blood Service Jorma Isola – Professor, UTA Matti Lehto – Director, UTA Jyrki Liljeroos – President, Santen Jukka Lekkala – Professor, TUT Tiina Äijälä – Director of Administration, TUT

3 BMT Research Groups TUT (156) UTA (232)

4 Mission BioMediTech’s mission is to promote and take responsibility for the research and the development of operational preconditions of biotechnology and related technical sciences. The Institute's mission, within the framework of its strategy, is to take for assessment and further development the potential innovations emerging from research, as well as their appropriate protection for further commercial utilization. As part of the innovation development process BMT's mission is also to make preparations and supervise the optimal commercialization of the potential products. Suomeksi: BioMediTechin tehtävänä on edistää ja vastata bioteknologian ja siihen liittyvän tekniikan alan tutkimuksesta sekä sen toimintaedellytysten kehittämisestä. Instituutin tehtävänä on strategiansa puitteissa ottaa arvioitavaksi ja edelleen kehitettäviksi tutkimuksen piiristä nousevat potentiaaliset innovaatiot sekä suojata ne asianmukaisesti kaupallista hyödyntämistä silmällä pitäen. Osana innovaation kehittämisprosessia BMT:n tehtävänä on myös valmistella ja valvoa potentiaalisten tuotteiden optimaalinen kaupallistaminen.

5 Innovation Challenge Regulatory knowhow Research Market Innovation
Product ? Clinical program Non-clinical, POC FTO Protection Business knowhow IPR knowhow

6 Human Spare Parts Program – CONCEPT
NEW THERAPIES / in vitro DISEASE MODELS BONE NEURAL OPHTHALMIC CARDIAC NEW TEHCNOLOGIES NEW TEHCNOLOGIES BIOMATERIALS IMAGING TISSUES CELLS & MICRO & NANOSYSTEMS SENSORS

7 Materials & supplies for research use
Innovation Pipeline Treatment modalities Diagnostics, in vitro models Materials & supplies for research use AlloBone (cranio facial bone) COPLA (knee cartilage) Incontinence Cornea/retina-injuries Kurko (biomaterials) SpikeBooster Hydrogel pyramide customMEA CARDIO-TUTL Myelinisation model 3DNeuron DrugPermeA TUTL miniPET CORE KNOW-HOW State-ot-the-Art INFRASTRUCTURE INTEGRATED INNOVATION SUPPORT

8 BMT Operational Model R&D SERVICES RESEARCH AREAS CORE FACILITIES
Personal Health Informatics Medical Biotechnology CORE FACILITIES CORE FACILITIES Regenerative Medicine Sensor Technology, Biomeasurements Regea Cell & Tissue Center Zebra Fish Laboratory Financing IPR & Legal Business Development Commercialization Quality & Regulatory Project Management Communications Biological Physics Microscopy & Histology Health Technology Fruit Fly Laboratory Immunology GMP Laboratory Mitochondria CellTech Flow Cytometry Computational Neuroscience Sensor systems Micro CT Microfabrication Computational Biophysics iPS Cells Micro- and nanosystems MEA Laboratory Sequencing Images, Signals & Models Cancer Electrophysiol. Measurements Virus Production Biomaterials and Tissue Engineering Computational Biology and Systems Biology High Power Computing Capacity Protein Technologies Physiological Measurements R&D SERVICES

9 BMT Servives for Researchers

10 Tampere 3 BIO, MED and TECH Campus
TAMK KAUPPI BioMediTech

11